<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04177290</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI308K101</org_study_id>
    <nct_id>NCT04177290</nct_id>
  </id_info>
  <brief_title>A Phase I PK Similarity Study of Sintilimab by Different Production Process in Advanced or Metastatic NSCLC Patients</brief_title>
  <official_title>A Phase I PK Similarity Study of Sintilimab by Different Production Process in Advanced or Metastatic NSCLC Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      this is a phase I study comparing PK similarity of sintilimab by different production process
      (approved versus M1b) in Chinese advanced or metastatic NSCLC patients who have failed or
      been intolerant to at least one prior line of standard treatment
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK is defined as AUC0-∞.</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK is defined as Cmax.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of sintilimab (approved) versus sintilimab (M1b). AE is defined as treatment-related adverse events assessed by CTCAE v5.0.</measure>
    <time_frame>from randomization through 90 days after last dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Advanced or Metastatic NSCLC</condition>
  <arm_group>
    <arm_group_label>sintilimab (M1b) 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sintilimab (approved) 200mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab (M1b)</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>sintilimab (M1b) 200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab (approved)</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>sintilimab (approved) 200mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Histologically or cytologically confirmed locally advanced, recurrent or metastatic
             NSCLC patients who have received or been intolerant to at least one prior line of
             standard treatment.

          2. No EGFR mutation or ALK rearrangement.

          3. ECOG PS score 0 or 1.

          4. BMI ≥ 21.0kg/m2 and ≤ 26.0kg/m2

          5. Body weight ≥ 60.0kg and ≤ 75.0kg.

          6. Adequate organ function per protocol-defined criteria.

        Exclusion criteria

          1. Exposure to any anti-PD-1, PD-L1, PD-L2 antibodies.

          2. Allergic to any component of sintilimab.

          3. Active autoimmune diseases.

          4. Clinically unstable central nervous system metastasis.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>yang yu</last_name>
    <phone>8618543019933</phone>
    <email>yang.yu@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>huan Zhou</last_name>
      <phone>0552-3086943</phone>
    </contact>
    <contact_backup>
      <last_name>Zishu Wang</last_name>
      <phone>0552-3086943</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

